TAO Synergies Inc. $TAOX

What the company doesAI summary of filing

TAO Synergies Inc., formerly known as Synaptogenix, Inc., is a company that historically developed biopharmaceutical products, primarily Bryostatin-1, a drug candidate for treating Alzheimer's disease and other neurodegenerative conditions, which remains in clinical development. In June 2025, the company shifted its primary strategy to a cryptocurrency treasury approach, purchasing and staking TAO tokens (the native cryptocurrency of the Bittensor blockchain, a decentralized network for machine learning and AI) with the goal of generating revenue through staking rewards and capital appreciation. The company allocates a substantial portion of its excess cash to TAO purchases and holds its assets through custodial arrangements, currently staking TAO through designated validators. The company is transitioning from a clinical-stage biopharmaceutical company to one focused on digital asset treasury management, while maintaining its pharmaceutical development platform. [10-K 2026-03-31]

Segments: Bryostatin-1 (Alzheimer's disease and neurodegenerative disorders), TAO cryptocurrency staking and treasury strategy, The TAO Daily (media and news platform)